Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in temozolomide-refractory glioblastoma multiforme (phase 2)
2013-001550-98Phase 2Terminated
- Sponsor
- University Hospital Ulm
- Start
- Jul 2013
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cabazitaxel in glioblastoma (GBM), sponsored by University Hospital Ulm. Primary endpoint: Tumor response by modified RANO criteria. Started Jul 2013; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2013-001550-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001550-98.